The Federal Trade Commission's global settlement with Teva Pharmaceutical Industries Ltd. is a victory for the agency in its campaign to eliminate so-called pay-for-delay deals between brand and generic companies that include side deals and commitments by the brand not to launch an authorized generic.
The settlement, announced Feb. 19, resolves claims against Teva in three pending FTC antitrust lawsuits and expands the terms in...







